Anaveon
develops and commercializes immunotherapeutic drugs for the prevention and treatment of cancer... Read moreAnaveon
develops and commercializes immunotherapeutic drugs for the prevention and treatment of cancer... Read more
News
Oct 30, 2024
Benzinga
Anaveon: Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Aug 02, 2024
Startupticker
Anaveon: Seasoned chairpersons and board members back life sciences startups
Jun 11, 2024
startupticker
Anaveon: Biotech startups make clinical progress
May 29, 2024
Life Care News
Anaveon: Anaveon announces IND approval of ANV600-001 (EXPAND) Phase
Dec 14, 2023
MarketScreener
Anaveon: Syncona : Anaveon announces publication of ANV419 Phase I data in The Journal for ImmunoTherapy of Cancer
Oct 27, 2023
Pharamceutical Technology
Anaveon: ANV-419 by Anaveon for Colorectal Cancer: Likelihood of Approval
Mar 23, 2023
Life Care News
Anaveon: Anaveon announces presentation of a novel development
Mar 17, 2023
Pharmabiz
Anaveon: Anaveon begins patient dosing in phase I/II study of ANV419 to treat multiple myeloma
Nov 30, 2022
Marketscreener
Anaveon: Syncona : Anaveon appoints Dr Eduard Gasal as Chief Medical Officer
Sep 19, 2022
startupticker
Anaveon: Encouraging results for Anaveon's lead molecule
Anaveon Competitors
1
2
3
4
5
6
7
8
9
10